Table 1.

Clinical Characteristics.

	N (%) and/or Median (Range)
Maternal Demographics (n = 29)
Age at Delivery (years)	27.4 (17.2 – 43.2)
Weight at Delivery (kg)	94.3 (72.5 – 124.2)
Race/Ethnicity – Black Non-Hispanic; Hispanic (Regardless of Race)	18 (62%); 11 (38%)
Concomitant ARVs 2T PK visit: FTC; TAF; 3TC; ZDV; TDF; DTG; LPV; RTV	10 (62.5%); 8 (50%); 6 (37.5%); 6 (37.5%); 2 (12.5%); 1 (6.25%); 1 (6.25%); 1 (6.25%)
Concomitant ARVs 3T PK visit: FTC; ZDV; TAF; 3TC; TDF; DTG; LPV; RTV	15 (57.7%); 12 (46.2%); 11 (42.3%); 9 (34.6%); 4 (15.4%); 3 (11.5%); 1 (3.8%); 1 (3.8%)
Country: United States	29 (100%)
2T: HIV-1 RNA ≤ 50 copies/mL; HIV-1 RNA copies/mL	11/16 (68.8%); 20 (20, 684)
2T: CD4 (cells/mm3)	506.5 (237 – 1596)
3T: HIV-1 RNA ≤ 50 copies/mL; HIV-1 RNA copies/mL	21/25 (84.0%); 20 (20, 124)
3T: CD4 (cells/mm3)	473 (153 – 1581)
Delivery: HIV-1 RNA ≤ 50 copies/mL; HIV-1 RNA copies/mL	25/29 (86.2%); 20 (20, 429)
Delivery: CD4 (cells/mm3)	517 (153 –1822)
PP: HIV-1 RNA ≤ 50 copies/mL; HIV-1 RNA copies/mL	15/19 (78.9%); 24 (20, 822)
PP: CD4 (cells/mm3)	569 (322 – 1807)
Infant Demographics (n=28)*
Gestational Age (weeks)	38.0 (35.9 – 40.9)
Birth Weight (grams)	2912.5 (2400–3800)
HIV Status: Uninfected; No testing data available	26 (93%); 2 (7%)

2T, second trimester; 3T, third trimester; PP, postpartum; PK, pharmacokinetic; FTC, emtricitabine; TAF, tenofovir alafenamide; 3TC, lamivudine; ZDV, zidovudine; TDF, tenofovir disoproxil fumarate; DTG, dolutegravir; LPV, lopinavir; RTV, ritonavir

^*One mother went off study before delivery